Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363909 · ClinicalTrials.gov registry record · Phase 3
Citalopram in Treating Postmenopausal Women With Hot Flashes
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 254
- Enrollment target
NCT00363909: Completed Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
NCT00363909 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 254 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00363909, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 254 participants
- Enrollment target
Study Summary
RATIONALE: Citalopram may help relieve hot flashes in women who had or have not had breast cancer. It is not yet known which dose of citalopram is more effective in treating hot flashes in postmenopausal women. PURPOSE: This randomized phase III trial is studying three different doses of citalopram to compare how well they work in treating postmenopausal women with hot flashes.
Interventions
- OTHER placebo
- DRUG citalopram hydrobromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
What the finished NCT00363909 record still lists
NCT00363909 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00363909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00363909 about?
NCT00363909 is a clinical study titled "Citalopram in Treating Postmenopausal Women With Hot Flashes". RATIONALE: Citalopram may help relieve hot flashes in women who had or have not had breast cancer. It is not yet known which dose of citalopram is more effective in treating hot flashes in postmenopausal women. PURPOSE: This randomized phase III trial is studying three different doses of citalopram...
What is the current status of trial NCT00363909?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 254 participants. The study started on 2006-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00363909?
The interventions under investigation include: placebo (OTHER), citalopram hydrobromide (DRUG).
Who is sponsoring clinical trial NCT00363909?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00363909's enrollment target sits among peer trials
254 1245th of 2000 higher than 755 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia